Hengrui Pharma, founded in 1970 and listed on the Shanghai Stock Exchange in 2000, is a global innovative pharmaceutical company specializing in the development, manufacturing, and commercialization of high-quality drugs. With a focus on the R&D of new drugs in the fields of anti-tumor, metabolic diseases, autoimmune diseases, respiratory diseases, and nervous system diseases, we are among the most innovative leading pharmaceutical companies in China.

For over 5 decades, Hengrui has remained committed to its original aspiration of serving patients, striving to safeguard their health and improve their quality of life, and driving the high-quality development of the pharmaceutical industry of China despite difficulties. Hengrui has been on the Pharma Exec’s annual listing of the top global pharmaceutical companies for six consecutive years. According to the list of the world's top 25 pipeline-scale pharmaceutical companies released by Citeline, an internationally renowned consulting organization, Hengrui was on the list for the third time, ranking 8th, setting a new high for Chinese pharmaceutical companies. And ranked 366th in
the list of "2023 Hurun Global 500" released by Hurun Research Institute.